Skip to main content

Topline results of the first cohort of our AZP-3601 study in hypoparathyroidism patients.

Amolyt Presented a released on "Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States" at the NEXAN Igniting Action 2021 conference in Denver.

There has been a shipment delay of NATPARA 75mcg. Patients will be receiving alternate prescriptions, temporarily. They will revert back to their original prescription once available.

Explanation from Takeda on supply disruption

Amolyt Pharma will be presenting three abstracts at the 23rd European Congress of Endocrinology (e-ECE) 2021.

We are incredibly excited to share that Calcilytix, a Bridgebio Company, announced early results from an ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Free genetic testing for AD-H1 now available for patients with non-surgical HypoPara.

AZP-3601 is currently in development for the treatment of hypoparathyroidism

The study will be conducted at the National Institutes of Health.

The Voices of Hypopara survey highlights the experiences of patients in the U.S. who are living with Hypopara.

This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.